Clinical data continues to demonstrate that tumours which are more visible to the immune system show improved responses to checkpoint inhibitors. Grey Wolf has developed unique insight into the targeting of the ERAP enzymes and validated the role for ERAP inhibition in modulating the cancer-related antigen repertoire. These in-house data provide compelling evidence that the therapies could have a real impact in the treatment of oncology. Grey Wolf combines first class drug discovery, in depth investigative biology, with biomarker discovery and development to guide clinical development.

Target
Stage
DiscoveryPreclinicalCandidate Nomination IND/CTA enabling
Immuno-oncology
ERAP1
  • IND/CTA enabling
ERAP1
(follow on molecules)
  • Preclinical
ERAP2
  • Discovery

The above information is accurate as of January 2021. The safety and efficacy of these investigation molecules is yet to be established. There is no guarantee that these molecules will proceed to market and become commercially available as these are agents in drug development could be terminated during the development process.